Document Detail

Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
MedLine Citation:
PMID:  9491919     Owner:  NLM     Status:  MEDLINE    
In an effort to induce a strong immune response that might protect against feline immunodeficiency virus (FIV) challenge infection, three groups of five specified pathogen-free (spf) cats each were immunized subcutaneously with different FIV antigen preparations. Immunizations were done at weeks 0, 2, and 4 with 100 microg of recombinant SU from an FIV Zurich 2 (FIV Z2) strain expressed by E. coli (group 1) or the baculovirus expression system (groups 2 and 3) adsorbed on aluminum hydroxyde and administered with QS-21 (groups 1 and 2) or Freund's adjuvant together with the recombinant nucleocapsid protein (protein NC) of rabies virus (group 3). Protein NC was described to act as an exogenous superantigen. Group 3 cats demonstrated the highest detectable antibody response to the vaccine antigen as determined by ELISA and Western blot analysis. All immunized cats together with seven control animals were challenged with 20 CID50 of cat lymphocyte-grown FIV Z2 3 weeks following the last immunization. Whereas virus was readily recovered from peripheral blood lymphocytes of seven of seven nonvaccinated control cats following this challenge dose, virus was not recovered from two cats of groups 1 and 2. All cats in groups 2 and 3 showed a provirus load significantly decreased to 3% of that of controls up to week 8 after challenge infection. Eleven of 15 vaccinated cats and 5 of 7 control cats developed virus-neutralizing antibodies by week 8 after challenge infection. The two cats negative on virus isolation remained seronegative, developed no detectable virus-neutralizing activities, but were repeatedly positive in provirus PCR. Moreover, starting at week 1 after challenge, both cats showed the lowest provirus load in their respective groups. These results indicate that immunization with recombinant FIV SU in conjunction with appropriate adjuvants may lead to partial protection against FIV challenge infection.
C M Leutenegger; R Hofmann-Lehmann; E Holznagel; A M Cuisinier; C Wolfensberger; V Duquesne; J Cronier; K Allenspach; A Aubert; P Ossent; H Lutz
Related Documents :
6274139 - Interaction of feline sarcoma virus (fesv) and mycoplasma.
6306469 - The hardy-zuckerman 2-fesv, a new feline retrovirus with oncogene homology to abelson-m...
8312659 - Diseases among men living in human t-lymphotropic virus type i endemic areas in japan.
7996159 - Virus neutralization reveals antigenic variation among feline immunodeficiency virus is...
8391229 - Evaluation of cofactor effect of feline syncytium-forming virus on feline immunodeficie...
11531409 - The bet gene of feline foamy virus is required for virus replication.
19593929 - Primary diagnosis and surveillance of white spot syndrome virus in wild and farmed craw...
3483029 - A serological survey for human immunodeficiency virus types 1 and 2 of individuals who ...
25274079 - Spinal cord compression by b-cell lymphoma, unclassifiable, with features intermediate ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  14     ISSN:  0889-2229     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-04-02     Completed Date:  1998-04-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  275-83     Citation Subset:  IM; X    
Clinical Laboratory, Department of Internal Veterinary Medicine, University of Zurich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic
Baculoviridae / genetics
Blotting, Western
Enzyme-Linked Immunosorbent Assay
Feline Acquired Immunodeficiency Syndrome / prevention & control*
Freund's Adjuvant / immunology
Immunodeficiency Virus, Feline / immunology*,  isolation & purification
Nucleocapsid Proteins / immunology
Polymerase Chain Reaction
Rabies virus / immunology
Saponins / immunology
Vaccines, Synthetic / immunology*
Viral Envelope Proteins / immunology*
Viral Vaccines / immunology*
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Nucleocapsid Proteins; 0/Saponins; 0/Vaccines, Synthetic; 0/Viral Envelope Proteins; 0/Viral Vaccines; 9007-81-2/Freund's Adjuvant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Severe combined immunodeficient mice engrafted with macaque peripheral blood leukocytes support repl...
Next Document:  Phosphatidate phosphatase--a key enzyme in glycerolipid biosynthesis. Studies on the yeast enzyme.